• 1
    Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 121824.
  • 2
    Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003; 157: 24955.
  • 3
    Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9: 15571.
  • 4
    Peura D. Helicobacter pylori: rational management options. Am J Med 1998; 105: 42430.
  • 5
    DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794811.
  • 6
    WHO. Adherence to Long-Term Therapies. Evidence for Action [Internet], Vol. 2008. Geneva: World Health Organization, 2003.
  • 7
    Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130: 5729.
  • 8
    Morris A, Brennan G, MacDonald T, Donnan P. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000; 49: A76.
  • 9
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296310.
  • 10
    Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease [see comment]. Am J Gastroenterol 2007; 102: 141726.
    Direct Link:
  • 11
    Cerveny P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13: 12449.
  • 12
    Lopez SR, Bermejo F, Carrera E, Perez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 24957.
  • 13
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1918.
  • 14
    Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease [see comment]. Am J Gastroenterol 2003; 98: 153544.
    Direct Link:
  • 15
    Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 21659.
  • 16
    Nigro G, Angelini G, Grosso SB, Caula G, Sategna-Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001; 32: 668.
  • 17
    Van Hees PA, Van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 3336.
  • 18
    Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis [Review] [59 refs]. Aliment Pharmacol Ther 2006; 23: 57785.
  • 19
    Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 20
    Moody GA, Jayanthi V, Probert CS, Mac KH, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 117983.
  • 21
    Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 2005; 100: 13546.
    Direct Link:
  • 22
    Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008; 14: 26574.
  • 23
    Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 19419.
  • 24
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 134553.
    Direct Link:
  • 25
    Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988; 26: 81423.
  • 26
    Hall NJ, Rubin GP, Hungin APS, Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterol. 2007; 7: 20.
  • 27
    Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12: 110713.
  • 28
    Klugmann HJ, Giehler B, Lohmann D, Schiedewitz W. Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration [German]. Gastroenterol J 1990; 49: 1604.
  • 29
    Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn’s disease. Aliment Pharmacol Ther 2007; 26: 21725.
  • 30
    Cerveny P, Lukas M, Bortlik M, Kubena A, Vlcek J Non-adherence to medicamentuous treatment of inflammatory bowel disease and its most frequent forms. Cesk Gastroenterol Hepatol 2006; 60: 20712 [Czech].
  • 31
    Bertomoro P, Vettorato M, Mazzocco K, Rumiati R, Sturniolo G, D’Inca R. Adherence to Medication in Inflammatory Bowel Disease Patients. Digestive Disease Week, Vol. 132. Washington, DC: American Gastroenterological Association, 2007: A344.
  • 32
    Mackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 100612.
  • 33
    Oliva-Hemker MM, Abadom V, Cuffari C, Thompson RE. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr 2007; 44: 1804.
  • 34
    Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005; 19: 23544.
  • 35
    Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 1703.
  • 36
    Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980; 1: 514.
  • 37
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 10418.
  • 38
    Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008; 53: 10204.
  • 39
    Kane S, Shaya F, El-Khoury A. Poor compliance with 5-ASA therapy in patients with gastrointestinal disorders increases the burden on healthcare services: a retrospective survey in Maryland, USA. In: America CsaCFo, ed. Advances in IBD, Vol. 13. Miami, FL: Crohn’s and Colitis Foundation of America, 2007: 664.
  • 40
    Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 2001; 7: 8617.
  • 41
    Fendrick AM, Chernew ME. Value-based insurance design: a “clinically sensitive, fiscally responsible” approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med 2007; 22: 8901.
  • 42
    Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005; 143: 8999.
  • 43
    Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 173342.
    Direct Link:
  • 44
    Kane S. Medication adherence and the physician-patient relationship. Am J Gastroenterol 2002; 97: 1853.
    Direct Link:
  • 45
    Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 54050.
  • 46
    Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 18814.
  • 47
    Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994; 22: 26672.
  • 48
    Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005; 7: 7228.